Skip to main content

Advertisement

Table 1 Demographics of all participants included in group and subgroup analyses

From: Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome

  All participants Dementia (baseline) No dementia (baseline) Participants with follow-up data
Number of subjects 94 18 76 29
Age at baseline, years, mean ± SD (range) 42.68 ± 14.87 (17–73) 55.17 ± 9.92 (40–69) 39.72 ± 14.34 (17–73) 52.63 ± 8.88 (40–72)
DS type 89 (94.7%) trisomy, 2 (2.1%) translocation, 3 (3.2%) unknown 18 (100.0%) trisomy 71 (93.4%) trisomy, 2 (2.6%) translocation, 3 (3.9%) unknown 28 (96.6%) trisomy, 1 (3.4%) unknown
Sex 41 (43.6%) female, 53 (56.4%) male 6 (33.3%) female, 12 (66.7%) male 35 (46.1%) female, 41 (55.9%) male 10 (34.5%) female, 19 (65.5%) male
Ethnicity 85 (90.4%) white, 9 (9.6%) other 17 (94.4.0%) white, 1 (5.6%) other 68 (89.5%) white, 8 (10.5%) other 27 (93.1%) white, 2 (6.8%) other
Predementia ID level 37 (39.4%) mild, 47 (50%) moderate, 9 (9.6%) severe, 1 (1.2%) unknown 6 (33.3%) mild, 9 (50.0%) moderate, 3 (16.7%) severe 31 (40.8%) mild, 38 (50%) moderate, 6 (7.9%) severe, 1 (1.3%) unknown 13 (44.8%) mild, 12 (41.4%) moderate, 3 (10.3%) severe, 1 (3.4%) unknown
APOE status 68 (72.3%) non-APOE4 carrier, 23 (24.5%) APOE4 carrier, 3 (3.2%) unknown 12 (66.7%) non-APOE4 carrier, 5 (27.8%) APOE4 carrier, 1 (5.5%) unknown 56 (73.7%) non-APOE4 carrier, 18 (23.7%) APOE4 carrier, 2 (2.6%) unknown 22 (75.9%) non-APOE4 carriers, 6 (20.7%) APOE4 carrier, 1 (3.4%) unknown
NF-L level, ng/L, median (range) 22.74 (6.11–136.91) 63.76 (15.21–136.91) 19.96 (6.11–116.84) 32.67 (12.23–481.97)
  1. Abbreviations: DS Down syndrome, ID Intellectual disability, APOE Apolipoprotein E, APOE4, Apolipoprotein E E4 allele, NF-L Neurofilament light